Trials

Participating Trials

SMART-C comprises all 13 completed SGLT2 inhibitor outcome trials, which include more than 90,000 patients with diabetes, heart failure or chronic kidney disease. Several SGLT2 inhibitor outcome trials are ongoing. These trials will be invited to join the Consortium once the trials are completed.

EMPA-REG OUTCOME

Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients

CANVAS Program

Canagliflozin Cardiovascular Assessment Study Program

DECLARE-TIMI 58

Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58

CREDENCE

Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation

DAPA-HF

Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure

EMPEROR-Reduced

Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and Reduced Ejection Fraction

DAPA-CKD

Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease

VERTIS-CV

Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease

SCORED

Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

SOLOIST-WHF

Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure

EMPEROR-Preserved

Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction

DELIVER

Dapagliflozin Evaluation to Improve the LIVEs of Patients With Preserved Ejection Fraction Heart Failure

EMPA-KIDNEY

Study of Heart and Kidney Protection with Empagliflozin